Suppr超能文献

他克莫司在中国肾移植受者中与霉酚酸酯和泼尼松联合首次口服给药后的临床药代动力学

Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.

作者信息

Chen Y H, Zheng K L, Chen L Z, Dai Y P, Fei J G, Qiu J, Li J

机构信息

Department of Urology, the First Affiliated Hospital of Zhongshan University, Guangzhou, China.

出版信息

Transplant Proc. 2005 Dec;37(10):4246-50. doi: 10.1016/j.transproceed.2005.11.055.

Abstract

INTRODUCTION

Data on tacrolimus pharmacokinetics in combination with mycophenolate mofetil and prednisone are scarce in Chinese renal transplantation recipients. The purpose of this study was to detect interpatient pharmacokinetic variability of tacrolimus and to assess the predictability of individual tacrolimus concentrations at various times for the area under the curve (AUC) seeking to find the best sampling time for an abbreviated AUC to predict the total body exposure of tacrolimus after the first oral dose in Chinese renal transplantation recipients.

METHODS

Sixteen primary kidney transplant recipients were treated with methylprednisolone and antilymphocyte globulin for 3 days. The first tacrolimus oral dose (0.075 mg/kg) was given at day 3 posttransplant. Mycophenolate mofetil and prednisone were administered orally posttransplant. Blood samples were obtained at 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 8.0, and 12.0 hours after taking the first oral dose. Tacrolimus blood concentrations were measured by ELISA. Twelve-hour AUC (AUC12) for each patient was calculated using the linear trapezoid rule. Associations between the blood concentration at each sampling time point and the AUC12 were evaluated by Pearson correlation coefficients. Abbreviated sampling equations were derived by multiple, stepwise regression analyses performed using AUC12 as the dependent variables. The variance in the strength of association between predicted AUC (AUC(P)) and AUC12 was reflected by linear regression coefficients of multiple determinations.

RESULTS

In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL). The area of the maximum AUC12 was almost fourfold higher than that of the minimum AUC12. C12 significantly correlated with AUC(12) after the first tarcrolimus oral dose (r = .846, P < .001). C5, C8, and C3 showed better correlations: r = .924, .924, and .911, respectively. From stepwise multiple regression, C5 seemed to be the best predictor of total body exposure to tacrolimus (r = .92, r2 = .85). Alternatively, the concentrations at 5 and 1.5 hours or 5, 1.5, and 3 hours as an abbreviated AUC were as good as a full pharmacokinetic study (r = .97, r2 = .94, and r = .99, r2 = .99, respectively).

CONCLUSIONS

Tacrolimus AUC12 show remarkable interindividual variations after the first oral dose in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Although C12 is a good predictor of efficacy, C5 might be the best predictor of the first AUC12. A two-point sampling method using C5 and C1.5 or three-point sampling method using C5, C1.5, and C3 might be the best abbreviated AUC for a cost-effective tacrolimus monitoring strategy.

摘要

引言

在中国肾移植受者中,关于他克莫司与霉酚酸酯和泼尼松联合应用时的药代动力学数据较少。本研究的目的是检测他克莫司在患者间的药代动力学变异性,并评估不同时间点他克莫司个体浓度对曲线下面积(AUC)的预测能力,旨在为中国肾移植受者首次口服剂量后他克莫司的全身暴露量预测找到最佳的缩短AUC采样时间。

方法

16例初次肾移植受者接受甲泼尼龙和抗淋巴细胞球蛋白治疗3天。移植后第3天给予首次他克莫司口服剂量(0.075mg/kg)。移植后口服霉酚酸酯和泼尼松。首次口服剂量后0.5、1.0、1.5、2.0、3.0、5.0、8.0和12.0小时采集血样。采用酶联免疫吸附测定法测定他克莫司血药浓度。使用线性梯形法则计算每位患者的12小时AUC(AUC12)。通过Pearson相关系数评估每个采样时间点的血药浓度与AUC12之间的相关性。以AUC12为因变量,通过多元逐步回归分析推导缩短采样方程。预测AUC(AUC(P))与AUC12之间关联强度的方差通过多重测定的线性回归系数反映。

结果

16例患者的AUC12值在44.40ng·h/mL至158.01ng·h/mL范围内(均值=92.23±34.97ng·h/mL)。最大AUC12面积几乎是最小AUC12面积的四倍。首次口服他克莫司后,C12与AUC(12)显著相关(r = 0.846,P < 0.001)。C5、C8和C3显示出更好的相关性:分别为r = 0.924、0.924和0.911。通过逐步多元回归分析,C5似乎是他克莫司全身暴露量的最佳预测指标(r = 0.92,r2 = 0.85)。或者,5小时和1.5小时或5、1.5和3小时的浓度作为缩短AUC与完整药代动力学研究效果相当(分别为r = 0.97,r2 = 0.94,以及r = 0.99,r2 = 0.99)。

结论

在中国肾移植受者中,首次口服他克莫司联合霉酚酸酯和泼尼松后,AUC12显示出显著的个体间差异。虽然C12是疗效的良好预测指标,但C5可能是首次AUC12的最佳预测指标。采用C5和C1.5的两点采样法或C5、C1.5和C3的三点采样法可能是用于他克莫司监测策略且具有成本效益的最佳缩短AUC方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验